New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

Published Aug 26, 2020

New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

RET+ lung cancers are aggressive and have a poor prognosis, but new targeted drug selpercatinib (Retevmo) benefits more than 90% of patients who have this type of cancer.

NOW
PLAYING
Do Statins, a Cholesterol-Lowering Medication, Lower Cancer Risk? An Expert Explains
NOW
PLAYING
What's the Risk of Relapse After Non-Hodgkin Lymphoma Treatment?
NOW
PLAYING
Exciting New Options Are Available for Lymphoma Recurrence
NOW
PLAYING
Treatment Options for Non-Hodgkin Lymphoma When the First Therapy Doesn't Work
NOW
PLAYING
Drug Cocktail Helps to Keep Non-Hodgkin Lymphoma Under Control
NOW
PLAYING
Given Just 18 Months to Live, This Lung Cancer Survivor Proves the Power of Clinical Trials
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.